LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Epilepsy; Seizure, Absence
Intervention: lamotrigine (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, MD, Study Director, Affiliation: GlaxoSmithKline
Summary
This is an open-label study evaluating the efficacy and safety of lamotrigine (LTG) for the
treatment of newly-diagnosed typical absence seizures. Subjects will be children and
adolescents < 13 years of age. It will be conducted at multiple sites in the US. The study
will consist of 4 phases: Screen Phase (up to 1 week), Baseline Phase (24 hours),
Escalation Phase (up to 20 weeks) and Maintenance Phase (12 weeks). Subjects will receive
increasing doses of LTG according to the dosing schedule until attaining seizure freedom as
confirmed by hyperventilation (HV) for clinical signs and a 1-hr EEG at 2 consecutive weekly
visits. At that point, subjects will move into the 12-week Maintenance Phase. Subjects who
do not achieve seizure freedom upon reaching the maximum dose (10. 2mg/kg/day) with the
specified dose escalation will be discontinued from the study. During the Maintenance
Phase, the investigators will use their best effort to maintain the subjects at the
efficacious dose reached. If the subjects have unacceptable side effects or inadequate
seizure control, the doses of study drug can be increased or decreased as specified in the
dosing schedule. Safety will be assessed by monitoring adverse events, laboratory
assessments, and serum lamotrigine levels. Health outcomes assessments will also be
conducted.
Clinical Details
Official title: An Open-label Evaluation of LAMICTAL (Lamotrigine) Monotherapy for the Treatment of Newly-diagnosed Typical Absence Seizures in Children and Adolescents
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The proportion of subjects with no typical absence seizures for two consecutive weeks as confirmed by hyperventilation (HV) for clinical signs and 1-hour electroencephalogram (EEG)
Secondary outcome: Freq of seizures pre/post-treatment with lamotrigine, proportion of subjects with >=25, 50 and 75% decrease in seizure frequency, proportion of subjects with >=25, 50 and 75% decrease in clinical signs.
Eligibility
Minimum age: N/A.
Maximum age: 12 Years.
Gender(s): Both.
Criteria:
Inclusion criteria:
- Newly-diagnosed with absence epilepsy and never been treated with Anti-epileptic
drugs (AEDs).
- Diagnosis demonstrated on one of two 5-minute hyperventilation tests.
- Investigator must judge that the subject and parent/guardian are likely to comply
with all study procedures.
- Parent/guardian must given written informed consent. Subjects who are intellectually
able to understand the concepts and procedures of the protocol must give assent by
also signing the consent or by signing a separate assent form.
- Results of all screen assessments are judged to be clinically acceptable to the
investigator and do not indicate any reasons why entry into the study would be
contraindicated.
Exclusion criteria:
- Seizures are the result of a currently active, known, and identifiable intracerebral
lesion.
- Has partial or generalized tonic-clonic seizures.
- Has a progressive neurological disorder defined as being unstable for at least 12
weeks prior to the Screen Phase.
- Has a psychiatric disorder requiring medication, or has had a past psychiatric
condition that was both judged to be severe and required hospitalization.
- Has any clinically significant chronic cardiac, renal, or hepatic medical condition.
- Has a condition that affects the absorption, distribution, metabolism, or excretion
of drugs.
- Is currently taking any psychoactive drugs to treat hyperactivity disorder or
attention deficit disorder.
- Has taken any investigational drug within 12 weeks prior to the Screen Phase.
- Is sexually active.
- Is either pregnant (i. e., confirmed by pregnancy test at Screen) or breastfeeding.
- Has a clinically significant chronic medical disorder which the investigator and/or
GSK medical monitor determine warrants exclusion.
Locations and Contacts
GSK Investigational Site, San Jose, California 95128, United States
GSK Investigational Site, Loxahatchee, Florida 33470, United States
GSK Investigational Site, Melbourne, Florida 32901, United States
GSK Investigational Site, Panama City, Florida 32405, United States
GSK Investigational Site, Tallahassee, Florida 32308, United States
GSK Investigational Site, Tampa, Florida 33607-6350, United States
GSK Investigational Site, Atlanta, Georgia 30342, United States
GSK Investigational Site, Louisville, Kentucky 40202, United States
GSK Investigational Site, Springfield, Missouri 65804, United States
GSK Investigational Site, Newark, New Jersey 07103, United States
GSK Investigational Site, Buffalo, New York 14222, United States
GSK Investigational Site, Rochester, New York 14642, United States
GSK Investigational Site, Chapel Hill, North Carolina 27599-7600, United States
GSK Investigational Site, Greenville, North Carolina 27834, United States
GSK Investigational Site, Raleigh, North Carolina 27607, United States
GSK Investigational Site, Germantown, Tennessee 38138, United States
GSK Investigational Site, Fort Worth, Texas 76104, United States
GSK Investigational Site, Seattle, Washington 98105, United States
GSK Investigational Site, Milwaukee, Wisconsin 53226, United States
Additional Information
Starting date: November 2004
Last updated: March 17, 2011
|